Xenon Pharmaceuticals XENE Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's total equity?
- Xenon Pharmaceuticals (XENE) reported total equity of $1.34B in Q1 2026.
- How has Xenon Pharmaceuticals's total equity changed year-over-year?
- Xenon Pharmaceuticals's total equity increased by 90.0% year-over-year, from $703.96M to $1.34B.
- What is the long-term trend for Xenon Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's total equity has grown at a 27.7% compound annual growth rate (CAGR), from $171.36M to $581.76M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.